What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...
The results from the PURPOSE 2 study, which build on the 100% efficacy shown in PURPOSE 1, demonstrate lenacapavir's unmatched clinical profile observed for HIV prevention. If approved, lenacapavir, ...
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...
Shanghai Daily on MSN1d
Patients to benefit from major CIIE purchasesCity-level hospitals purchase 14 large medical appliances, all from leading international companies, at the CIIE on Friday alongside cooperation on infectious disease management.
We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.
Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...
Zacks.com on MSN2d
Gilead Beats on Q3 Earnings and Sales, Raises Annual OutlookGilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...
Gilead Q3 profits soar, boosting full-year earnings forecast with strong HIV & COVID-19 treatment sales. Discover their impressive growth story.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback